LENZ_OUT_1 [2025-04-29 07:01:19 -0400] 4777 Bytes | 1312 tokens | Cum: 1312 tkns (16.40% of 8k)
==========================================================================

Alright, let’s light it up, because it's 7:01 AM on Tue Apr 29, 2025, and I'm charging into LENZ Therapeutics (LENZ), popping from $26.87 to $29.90. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: LENZ Therapeutics (LENZ)
IPO: IPO date unknown
Shares Outstanding: 27,540,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS

Here’s a list of headlines for LENZ Therapeutics:

Apr-07-25 08:00AM - LENZ Therapeutics: Freedom From Reading Glasses
Apr-01-25 07:00AM - Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Mar-27-25 05:33PM - LENZ Therapeutics Stock Is Attractive Before PDUFA
Mar-19-25 08:09PM - Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress
Mar-19-25 08:09PM 08:09PM - LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript
Mar-19-25 08:09PM 04:05PM - LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Mar-11-25 08:00AM - LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
Mar-03-25 08:00AM - LENZ Therapeutics to Host Commercial Day on April 15, 2025
Feb-24-25 08:00AM - LENZ Therapeutics to Participate in Upcoming Investor Conferences
Nov-12-24 08:00AM - LENZ Therapeutics to Participate in Upcoming Investor Conferences
Nov-06-24 07:00AM - LENZ Therapeutics Reports Third Quarter 2024 Financial Results
Oct-30-24 08:00AM - LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
Oct-27-24 09:00PM - CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
Oct-22-24 08:10AM - Lenz Therapeutics announces FDA acceptance of NDA for LNZ100
Oct-21-24 08:00AM - LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
Sep-30-24 08:00AM - LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
Aug-27-24 04:01PM - LENZ Therapeutics to Participate in Upcoming Investor Conferences
Aug-14-24 04:05PM - LENZ Therapeutics Reports Second Quarter 2024 Financial Results
Aug-12-24 08:00AM - LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
Aug-07-24 04:01PM - LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
Jul-15-24 08:00AM - LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
Jun-10-24 08:00AM - LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-06-10T12:00:00Z - LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
B2 - 2024-05-30T12:00:00Z - LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
B3 - 2024-05-08T20:01:00Z - LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
B4 - 2024-05-01T20:01:00Z - LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
B5 - 2024-04-10T19:19:01Z - Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for LENZ Therapeutics (LENZ).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

LENZ_OUT_3 [2025-04-29 07:01:19 -0400] 1166 Bytes | 300 tokens | Cum: 1614 tkns (20.18% of 8k)
==========================================================================

Showing B5 (chunk 1 of 1): B5:
**Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38190459/blindness-focused-lenz-therapeutics-investigational-eye-drop-ready-to-revolutionizeLast week, LENZ Therapeutics Inc (NASDAQ:LENZ) released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101.
Lead product candidate LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one line or more in distance visual acuity. 
Citi analyst writes that with promising Phase 3 ...Full story available on Benzinga.com

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LENZ_OUT_5 [2025-04-29 07:01:20 -0400] 889 Bytes | 283 tokens | Cum: 1899 tkns (23.74% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-25T01:39:27Z - LENZ - Long Trade Setup ! for NASDAQ:SEZL by ProfittoPath...
A2 - 2025-04-23T11:12:35Z - Rock Springs Capital Management LP Acquires New Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)...
A3 - 2025-04-18T12:05:20Z - LENZ Therapeutics' (LENZ) Buy Rating Reiterated at HC Wainwright...
A4 - 2025-04-17T14:41:57Z - LENZ Therapeutics (NASDAQ:LENZ) Shares Gap Up - Should You Buy?...
A5 - 2025-04-16T16:56:24Z - LENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 8.3% - Still a Buy?...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

LENZ_OUT_7 [2025-04-29 07:01:21 -0400] 1205 Bytes | 362 tokens | Cum: 2263 tkns (28.29% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**LENZ - Long Trade Setup ! for NASDAQ:SEZL by ProfittoPath**Date: 2025-04-25Source: {'uri': 'tradingview.com', 'dataType': 'news', 'title': 'TradingView'}URL: https://www.tradingview.com/chart/SEZL/yNDkrZAQ-LENZ-Long-Trade-Setup/📈 🟢

Ticker: LENZ Therapeutics, Inc. (LENZ - NASDAQ)

Timeframe: 30-Min Chart

Pattern: Rising wedge breakout with volume push

💼 Trade Plan - Long Position

✅ Entry: $28.60 (breakout above consolidation + structure reclaim)

🛑 Stop-Loss: $27.26 (below wedge base and breakout level)

🎯 Take Profit Targets:

TP1: $30.52 - Key resistance zone

TP2: $32.52 - Extended range target / breakout continuation zone

⚖️ Risk-Reward Calculation

Risk per Share: $1.34

Reward to TP2: $3.92

R:R Ratio: ~1 : 2.9 -- Strong long setup

🔍 Technical Highlights

Clean breakout of tight range wedge

Reclaim of horizontal resistance near $28

Rising trend with confirmation volume

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LENZ_OUT_9 [2025-04-29 07:01:21 -0400] 339 Bytes | 95 tokens | Cum: 2360 tkns (29.50% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2):

Momentum from mid-April forming consistent higher lows

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LENZ_OUT_11 [2025-04-29 07:01:22 -0400] 1088 Bytes | 292 tokens | Cum: 2654 tkns (33.17% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-15 8-K Item 2.02 Results of Oper and Fin Cond.

LENZ Therapeutics, Inc. (the Company) is filing this Curr Report on Form 8-K in connection with the previously announced Commercial Day to be held on April 15, 2025, to announce that the Companys cash, cash equiv...

S3 - 2025-04-04 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On April 4, 2025, LENZ Therapeutics, Inc. (the Company) entered into a Sales Agrmt (the Sales Agrmt) with TD Securities (USA) LLC (TD Cowen) to sell shares of the Companys common stock, par value $0.00001 per share (...

S4 - 2025-03-19 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis provides information that our management believes is relevant to an assessment and understanding of LENZ CONS results of operations and f...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

LENZ_OUT_13 [2025-04-29 07:01:23 -0400] 988 Bytes | 229 tokens | Cum: 2885 tkns (36.06% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition.

LENZ Therapeutics, Inc. (the Company) is filing this Current Report on Form 8-K in connection with the previously announced Commercial Day to be held on April 15, 2025, to announce that the Companys cash, cash equivalents and marketable securities were approximately $194 million as of March 31, 2025. This amount is unaudited and preliminary and is subject to completion of financial closing procedures. Our independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to these preliminary results and, accordingly, does not express an opinion or any other form of assurance about them....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

LENZ_OUT_15 [2025-04-29 07:01:28 -0400] 6345 Bytes | 1701 tokens | Cum: 4588 tkns (57.35% of 8k)
==========================================================================

This is our set of metrics for LENZ Therapeutics.
Please analyze the numbers.

+---------------------+----------------------+-------------------------+-----------------------+
| Volume: 205,680 | Perf Month: 2.81% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+----------------------+-------------------------+-----------------------+
| Avg Volume: 219.38K | Perf Quarter: 10.56% | Short Float: 12.80% | ROE: -25.68% |
+---------------------+----------------------+-------------------------+-----------------------+
| Rel Volume: 0.93 | Index: RUT | Short Ratio: 13.19 | ROI: -24.29% |
+---------------------+----------------------+-------------------------+-----------------------+
| RSI (14): 59.58 | Market Cap: 751.24M | Short Interest: 2.89M | Sales Surprise: - |
+---------------------+----------------------+-------------------------+-----------------------+
| ATR (14): 2.11 | Shs Outstand: 27.52M | Beta: 0.51 | EPS Surprise: -12.20% |
+---------------------+----------------------+-------------------------+-----------------------+
| SMA20: 15.56% | Shs Float: 22.61M | Sales Q/Q: - | P/E: - |
+---------------------+----------------------+-------------------------+-----------------------+
| SMA50: 14.11% | Inst Own: 79.20% | Sales past 5Y: 0.00% | Earnings: Mar 19 AMC |
+---------------------+----------------------+-------------------------+-----------------------+
| SMA200: 5.54% | Insider Own: 17.90% | Employees: 42 | |
+---------------------+----------------------+-------------------------+-----------------------+
| Perf Week: 13.13% | Insider Trans: 0.00% | Debt/Eq: 0.01 | |
+---------------------+----------------------+-------------------------+-----------------------+

The next section covers any insider trading by LENZ Therapeutics officers or majority shareholders (if available).

Inside Trans: LENZ Therapeutics, Inc. (LENZ) by Olsson Shawn (Chief Commercial Officer) on 2025-04-09
- Common Stock: 1400 shares at $2.08 (D)
- Stock Option (right to buy): 1400 shares at $0 (D)

Inside Trans: LENZ Therapeutics, Inc. (LENZ) by Schimmelpennink Evert B. (President, CEO and Secretary) on 2025-03-07
- Common Stock: 4200 shares at $1.04 (D)
- Stock Option (right to buy): 4200 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -49769000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 27.275
Average Volume: 320662.7
30-Day High: 28.61
30-Day Low: 18.32

[Detailed Financials: TTM 2024]
- Total Assets: $215,304,000.00
- Total Liabilities: $11,220,000.00
- Total Equity: $204,084,000.00
- Current Assets: $211,917,000.00
- Current Liabilities: $10,406,000.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-49,769,000.00
- Gross Profit: N/A
- Operating Income: $-58,610,000.00
- Earnings Per Share (EPS): -2.34

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-14,868,000.00

[Detailed Financials: FY 2024]
- Total Assets: $215,304,000.00
- Total Liabilities: $11,220,000.00
- Total Equity: $204,084,000.00
- Current Assets: $211,917,000.00
- Current Liabilities: $10,406,000.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-49,769,000.00
- Gross Profit: N/A
- Operating Income: $-58,610,000.00
- Earnings Per Share (EPS): -2.34

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-14,868,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of LENZ Therapeutics (LENZ).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about LENZ Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because LENZ is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for LENZ.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, LENZ could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect LENZ to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of LENZ Therapeutics.

11) ETHICAL_RATING[]
Rate LENZ Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of LENZ Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

LENZ_IN_17 [2025-04-29 07:01:28 -0400] 125 Bytes | 29 tokens | Cum: 4822 tkns (60.27% of 8k)
==========================================================================

====================================
[2025-04-29 07:01:28] # Analysis Completed
Elapsed Time: 9.92 seconds